.png){kind=icon}
返回
Armodafinil
.png){kind=icon}
PRE
AI
DOI：10.2165/11203290-000000000-00000.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Once-daily armodafinil was effective in improving wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome (OSA) [despite treatment of the underlying condition], narcolepsy or shift work sleep disorder (SWSD) in four large (n > 195), double-blind, multinational trials of 12 weeks' duration. Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). Furthermore, a significantly higher proportion of armodafinil than placebo recipients achieved a response (at least a minimal improvement) on the Clinical Global Impressions of Change (CGI-C) scale at study end in these four trials (coprimary endpoint). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.
Keyword:
WORK SLEEP DISORDER
HEALTHY-SUBJECTS
DOUBLE-BLIND
PHARMACOKINETIC PROFILE
APNEA/HYPOPNEA SYNDROME
MODAFINIL TABLETS
ADULTS
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.4
论文数:
2.5K
被引数:
7.0K
机构
引用论文
Regionalisation of anterior neuroectoderm and its competence in responding to forebrain and midbrain inducing activities depend on mutual antagonism between OTX2 and GBX2.png)
Development
OAAI
DevelopmentIF0
OAAI分享收藏Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndromeRESPIRATORY MEDICINEOAAI
RESPIRATORY MEDICINEIF3.1
OAAI分享收藏
分享收藏
查看更多内容